PRNP

Major prion protein · P04156 · PRNP on Sugi Atlas →

27,554 patent compounds predicted against PRNP, 17,486 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL414985 SCHEMBL414985 0.83 7/20
SCHEMBL947047 SCHEMBL947047 0.52 7/20
SCHEMBL862262 SCHEMBL862262 0.52 7/20
SCHEMBL859288 SCHEMBL859288 0.51 7/20
SCHEMBL847350 SCHEMBL847350 0.51 7/20
SCHEMBL342862 SCHEMBL342862 0.48 6/20
SCHEMBL857677 SCHEMBL857677 0.46 6/20
SCHEMBL860937 SCHEMBL860937 0.44 6/20
SCHEMBL419503 SCHEMBL419503 0.50 5/20
SCHEMBL728065 SCHEMBL728065 0.47 5/20
SCHEMBL859723 SCHEMBL859723 0.43 5/20
Promazine Promazine (SCHEMBL140489) 1.00 4/20
Promazine Promazine (SCHEMBL123418) 0.97 4/20
Promazine Promazine (SCHEMBL123419) 0.94 4/20
SCHEMBL618785 SCHEMBL618785 0.54 4/20
SCHEMBL400710 SCHEMBL400710 0.34 4/20
Chlorpromazine Chlorpromazine (SCHEMBL8321) 1.00 3/20
Acepromazine Acepromazine (SCHEMBL73018) 1.00 3/20
Chlorpromazine Chlorpromazine (SCHEMBL41771) 0.97 3/20
Chlorpromazine Chlorpromazine (SCHEMBL157752) 0.95 3/20

Clinical trials — most relevant to PRNP by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Dry Eye OmniLenz Application of Omnigen Research Study PHASE4COMPLETED
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) PHASE2/PHASE3ACTIVE_NOT_RECRUITING
Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD) PHASE2ACTIVE_NOT_RECRUITING
The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP) PHASE2COMPLETED
PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717 PHASE1/PHASE2RECRUITING
PrP-targeting siRNA Safety & Mechanism Study PHASE1RECRUITING
A Clinical Study to Evaluate the Safety of MF1, a New Treatment for Parkinson's Disease-related Disorders (MF1 Study) PHASE1RECRUITING
18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease PHASE1COMPLETED
Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease PHASE1COMPLETED
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and Frontotemporal Dementia PHASE1COMPLETED
[18F]ACI-19626 PET in TDP-43 Proteinopathies EARLY_PHASE1RECRUITING
Therapeutic Antibodies Against Prion Diseases From PRNP Mutation Carriers nanCOMPLETED
Biomarker Profiling in Individuals at Risk for Prion Disease nanRECRUITING
Visualising Cerebral and Peripheral Cholinergic Nerves in Patients With Dementia Lewy Bodies. nanCOMPLETED
Biology-Driven Cognitive Profiling in Huntington's Disease nanACTIVE_NOT_RECRUITING
Toward Molecular Profiling of Parkinson's Disease in Easily Accessible Biological Matrices nanACTIVE_NOT_RECRUITING
Establishing Alpha-synuclein RT-QuIC Assay as a Diagnostic Technique in REM Sleep Behaviour Disorder nanWITHDRAWN
Impact of Photobiomodulation (PBM) on Biomarkers of Alzheimer's Disease nanCOMPLETED
Natural History Characterization in Symptomatic and Asymptomatic Progranuline Gene Mutation Carriers nanCOMPLETED
Detection of A-synuclein Aggregate as Biomarker in Diagnosing Parkinson's Disease at Early Stage by Using Protein Misfolding Cyclic Amplification (PMCA) nanWITHDRAWN
Prodromal Markers of First-degree Relatives of Patients With Psychiatric Disorders Comorbid With RBD nanCOMPLETED
Biomarkers in Alzheimer's and Parkinson's Diseases for IA nanACTIVE_NOT_RECRUITING
A Natural History Study of Preclinical Genetic Creutzfeldt-Jakob Disease (CJD) nanRECRUITING
PRION-1: Quinacrine for Human Prion Disease nanCOMPLETED
Unstructured Eye Tracking as a Diagnostic and Prognostic Biomarker in Parkinsonian Disorders nanUNKNOWN
Identification of New FTLD Genes nanUNKNOWN
Proteinopathies Expression in Skin of Neurodegenerative Disorders nanRECRUITING
Exploring the Olfactory Mucosa, Blood and Urine for the Identification of Early Biomarkers of Parkinson's Disease, Atypical Parkinsonisms and Neurocognitive Disorders Due to Lewy Body Disease nanRECRUITING
Predict to Prevent PGRN Disease nanWITHDRAWN

Related proteins — ESM-2 sequence neighbours (a PRNP binder may also engage these)

ProteinNameSimilarity
P40256 1.000 P40256 →
P40257 1.000 P40257 →
P67995 1.000 P67995 →
P61761 1.000 P61761 →
P51446 1.000 P51446 →
Q5UJH0 1.000 Q5UJH0 →
Q6EH52 1.000 Q6EH52 →
P67993 1.000 P67993 →
P67997 1.000 P67997 →
B5SY89 1.000 B5SY89 →
Q95174 1.000 Q95174 →
Q60506 1.000 Q60506 →
O18754 1.000 O18754 →
P67996 1.000 P67996 →
P67988 1.000 P67988 →
P40258 1.000 P40258 →
P67990 1.000 P67990 →
P04925 1.000 P04925 →
P40246 1.000 P40246 →
P40245 1.000 P40245 →
Q5XVM4 1.000 Q5XVM4 →
P40249 1.000 P40249 →
P61768 1.000 P61768 →
Q9Z0T3 1.000 Q9Z0T3 →
Q5UAF1 1.000 Q5UAF1 →
Q5UJI7 1.000 Q5UJI7 →
P10279 1.000 P10279 →
P40243 1.000 P40243 →
O46501 1.000 O46501 →
P67992 1.000 P67992 →